188: AI in Pathology: Biomarkers, Multimodal Data & the Patient

Send a text

Is AI in pathology actually improving diagnosis — or just adding complexity?

In DigiPath Digest #37, we reviewed four recent publications covering AI-based biomarker quantification in glioblastoma, real-world digital workflow integration in prostate cancer, multimodal AI combining histopathology and genomics, and patient perspectives on AI in cancer diagnostics.

This episode connects technical performance with something equally important: trust.

Episode Highlights

[00:02] Community & updates
Digital Pathology 101 free PDF, upcoming patient-focused book, and global attendance.

[04:07] AI-based image analysis in glioblastoma
AI showed strong consistency with pathologists when quantifying Ki-67, P53, and PHH3.
Significant biological correlations (Ki-67 ↔ PHH3, PHH3 ↔ P53) were detected by AI — not by manual assessment.
Takeaway: computational quantification improves precision.

[09:28] Real-world digital workflow + AI in prostate cancer (France)
AI-pathologist concordance:
• 93.2% (high probability cancer detection)
• 99.0% (low probability slides)
Gleason concordance: 76.6%
10% failure rate due to pre-analytical artifacts.
Takeaway: infrastructure and sample quality still matter.

[15:58] Multimodal AI (MARBIX framework)
Combines whole slide images + immunogenomic data in a shared latent space using binary “monograms.”
Performance in lung cancer: 85–89% vs 69–76% unimodal models.
Takeaway: integrated data improves case retrieval and similarity reasoning.

[22:13] AI-powered paper summary subscription introduced
Structured summaries for busy professionals who want more than abstracts.

[26:17] Patient roundtable on AI in pathology (Belgium)
Patients expect:
• Better accuracy
• Faster turnaround
• Stronger collaboration

Trust is high when:
• Algorithms use diverse datasets
• Pathologists retain final responsibility

Clinical validity mattered more than full algorithm transparency.
Privacy concerns focused more on insurer misuse than cloud transfer.

Key Takeaways

• AI improves biomarker precision in glioblastoma.
• Digital pathology implementation works — but pre-analytics can limit AI performance.
• Multimodal AI represents the next meaningful step in precision diagnostics.
• Patients are not afraid of AI — they want validation, oversight, and governance.
• Human–AI collaboration remains central.

If you’re working in digital pathology, computational pathology, or precision oncology, this episode connects evidence, implementation, and patient perspective.

Support the show

Get the "Digital Pathology 101" FREE E-book and join us!